Capricor Therapeuticsincis A Clinical Stage Biotechnology Company Based In San Diegocaliforniait Focuses On Developing Cell And Exosome Based Therapeutics For Rare Diseases And Conditions With Significant Unmet Medical Needsthe Company Employs Around 160 Professionals And Has A Pipeline That Targets Muscular Dystrophiesheart Diseaseand Other Select Disorders Capricor Specializes In Biologicsparticularly Allogeneic Cardiosphere Derived Cellscdcsand Engineered Exosome Technologiesits Lead Productcap 1002Deramiocel Is A Phase 3 Allogeneic Cell Therapy Aimed At Treating Duchenne Muscular Dystrophydmdby Reducing Inflammation And Promoting Muscle Regenerationthe Company Also Offers The Stealthxa C Exosome Platformdesigned For Targeted Delivery Of Therapeutic Agentscapricor Collaborates With Academic Institutions To Advance Its Research In Cell And Exosome Sciencefocusing On Both Cell Therapy And Exosome Engineering
